Kogenate FS and Sertraline Oral Concentrate

• Generic Name: antihemophilic factor
• Dosage Forms: injection
• Other Brand Names: Advate, Adynovate, Afstyla, Eloctate with Fc Fusion Protein, Helixate FS, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil-M, Koate-DVI, Monoclate-P, Jivi, Obizur

Kogenate FS contains recombinant antihemophilic factor. Antihemophilic factor is a naturally occurring protein in the blood that helps blood to clot. A lack of antihemophilic factor VIII is the cause of hemophilia A.

Kogenate FS works by temporarily raising levels of factor VIII in the blood to aid in clotting.

Kogenate FS is used to treat or prevent bleeding episodes in adults and children with hemophilia A. It is also used to control bleeding related to surgery or dentistry in a person with hemophilia, and to prevent joint damage in people age 16 or older with severe hemophilia A and no prior joint damage.

Kogenate FS is not for use in people with von Willebrand disease.

• Generic Name: sertraline
• Dosage Forms: oral solution, concentrate
• Other Brand Names: Zoloft

Management of major depressive disorder.

Efficacy in hospital settings not established.

APA states that effectiveness of antidepressants is generally comparable between and within classes of medications, including SSRIs, SNRIs, TCAs, MAOIs, and other antidepressants (e.g., bupropion, mirtazapine, trazodone). Choose antidepressant based mainly on patient preference; nature of prior response to medication; safety, tolerability, and anticipated adverse effects; concurrent psychiatric and medical conditions; and specific properties of the medication (e.g., half-life, actions on CYP450 enzymes, other drug interactions). For most patients, an SSRI, SNRI, mirtazapine, or bupropion is considered optimal. Consult APA’s Practice Guidelines for the Treatment of Patients with Major Depressive Disorder for additional information.

Management of OCD; reduces but does not completely eliminate obsessions and compulsions.

Management of panic disorder with or without agoraphobia.

Management of PTSD; more effective in women than in men.

Not effective for combat- or war-related PTSD.

Management of PMDD; improves symptoms (e.g., depressed mood, premenstrual anger/irritability) and functional impairment (e.g., difficulty in concentrating, lethargy) associated with this disorder.

Efficacy when used in conjunction with oral contraceptives for the treatment of PMDD is unknown.

Management of social phobia (social anxiety disorder).

Has been used in the management of premature ejaculation.

Has been used in the management of vascular headaches with equivocal efficacy.